DARE

Company Overview — What Does Dare Bioscience, Inc. Do?

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California. Dare Bioscience, Inc. (DARE) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Sabrina M. Johnson and employs approximately 30 people, headquartered in LA JOLLA, California. With a market capitalization of $28M, DARE is one of the notable companies in the Healthcare sector.

Dare Bioscience, Inc. (DARE) Stock Rating — Reduce (April 2026)

As of April 2026, Dare Bioscience, Inc. receives a Reduce rating with a composite score of 25.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.DARE ranks #3,545 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Dare Bioscience, Inc. ranks #562 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DARE Stock Price and 52-Week Range

Dare Bioscience, Inc. (DARE) currently trades at $1.83. The stock lost $0.02 (1.1%) in the most recent trading session. The 52-week high for DARE is $9.19, which means the stock is currently trading -80.1% from its annual peak. The 52-week low is $1.39, putting the stock 31.7% above its annual trough. Recent trading volume was 88K shares, suggesting relatively thin trading activity.

Is DARE Overvalued or Undervalued? — Valuation Analysis

Dare Bioscience, Inc. (DARE) carries a value factor score of 14/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 9.07x, versus the sector average of 2.75x. The price-to-sales ratio is 534.57x, compared to 1.66x for the average Healthcare stock.

At current multiples, Dare Bioscience, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Dare Bioscience, Inc. Profitability — ROE, Margins, and Quality Score

Dare Bioscience, Inc. (DARE) earns a quality factor score of 8/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -586.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -51.3% versus the sector average of -33.1%.

On a margin basis, Dare Bioscience, Inc. reports gross margins of 71.3%, compared to 71.5% for the sector. The operating margin is -63862.1% (sector: -66.1%). Net profit margin stands at -62001.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -89.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DARE Debt, Balance Sheet, and Financial Health

Dare Bioscience, Inc. has a debt-to-equity ratio of 1042.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.14x, suggesting adequate working capital coverage. Total debt on the balance sheet is $10,542. Cash and equivalents stand at $23M.

DARE has a beta of 0.15, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Dare Bioscience, Inc. is 48/100, reflecting average volatility within the normal range for its sector.

Dare Bioscience, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Dare Bioscience, Inc. reported revenue of $48,208 and earnings per share (EPS) of $-1.20. Net income for the quarter was $-17M. Gross margin was 71.3%. Operating income came in at $-17M.

In FY 2025, Dare Bioscience, Inc. reported revenue of $1M and earnings per share (EPS) of $-1.20. Net income for the quarter was $-13M. Gross margin was 71.3%. Revenue grew 10429.4% year-over-year compared to FY 2024. Operating income came in at $-14M.

In Q3 2025, Dare Bioscience, Inc. reported revenue of $2,262 and earnings per share (EPS) of $-0.28. Net income for the quarter was $-4M. Revenue grew -94.6% year-over-year compared to Q3 2024. Operating income came in at $-4M.

In Q2 2025, Dare Bioscience, Inc. reported revenue of $-21,172 and earnings per share (EPS) of $-0.45. Net income for the quarter was $-4M. Revenue grew -194.4% year-over-year compared to Q2 2024. Operating income came in at $-4M.

Over the past 8 quarters, Dare Bioscience, Inc. has demonstrated a growth trajectory, with revenue expanding from $22,438 to $48,208. Investors analyzing DARE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DARE Dividend Yield and Income Analysis

Dare Bioscience, Inc. (DARE) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DARE Momentum and Technical Analysis Profile

Dare Bioscience, Inc. (DARE) has a momentum factor score of 23/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 68/100 reflects moderate short selling activity.

DARE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Dare Bioscience, Inc. (DARE) ranks #562 out of 838 stocks based on the Blank Capital composite score. This places DARE in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DARE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DARE vs S&P 500 (SPY) comparison to assess how Dare Bioscience, Inc. stacks up against the broader market across all factor dimensions.

DARE Next Earnings Date

No upcoming earnings date has been announced for Dare Bioscience, Inc. (DARE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DARE? — Investment Thesis Summary

The quantitative profile for Dare Bioscience, Inc. suggests caution. The quality score of 8/100 flags below-average profitability. The value score of 14/100 indicates premium valuation. Momentum is weak at 23/100, a headwind for near-term performance.

In summary, Dare Bioscience, Inc. (DARE) earns a Reduce rating with a composite score of 25.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DARE stock.

Related Resources for DARE Investors

Explore more research and tools: DARE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DARE head-to-head with peers: DARE vs AZN, DARE vs SLGL, DARE vs VMD.